References
- Burashnikov A, Antzelevitch C. Can inhibition of IKur promote atrial fibrillation? Heart Rhythm 2008;5:1304–9.
- Mulder BA, Schnabel RB, Rienstra M. Predicting the future in patients with atrial fibrillation: who develops heart failure? Eur J Heart Fail 2013;15:366–7.
- Nattel S, Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug Discov 2006;5:1034–49.
- Wolf PA, Mitchell JB, Baker CS, et al. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998;158:229–34.
- Brandt MC, Priebe L, Bohle T, et al. The ultrarapid and the transient outward K+ current in human atrial fibrillation. Their possible role in postoperative atrial fibrillation. J Mol Cell Cardiol 2000;32:1885–96.
- Brunner M, Kodirov SA, Mitchell GF, et al. In vivo gene transfer of Kv1.5 normalizes action potential duration and shortens QT interval in mice with long QT phenotype. AM J Physiol Heart Circ Physiol 2003;285:H194–H203.
- Yang Y, Li J, Lin X, et al. Novel KCNA5 loss-of-function mutations responsible for atrial fibrillation. J Hum Genet 2009;54:277–83.
- Olson TM, Alekseev AE, Liu XK, et al. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum Mol Genet 2006;15:2185–91.
- Wang YJ, Chen BS, Lin MW, et al. Time-dependent block of ultrarapid-delayed rectifier K+ currents by aconitine, a potent cardiotoxin, in heart-derived H9c2 myoblasts and in neonatal rat ventricular myocytes. Toxicol Sci 2008;106:454–63.
- Nerbonne JM, Kass RS. Molecular physiology of cardiac repolarization. Physiol Rev 2005;85:1205–53.
- Martens JR, Kwak YG, Tamkun MM. Modulation of Kv channel alpha/beta subunit interactions. Trends Cardiovas Med 1999;9:253–8.
- Tanabe Y, Hatada K, Naito N, et al. Over-expression of Kv1.5 in rat cardiomyocytes extremely shortens the duration of the action potential and causes rapid excitation. Biochem Biophys Res Commun 2006;345:1116–21.
- Wu SD, Fluxe A, Sheffer J, et al. Discovery and in vitro/in vivo studies of tetrazole derivatives as Kv1.5 blockers. Bioorg Med Chem Lett 2006;16:6213–8.
- Griffin A, Scott RH. Properties of K+ currents recorded from cultured ovine trachea submucosal gland-cells. Resp Physiol 1994;96:297–309.
- Rettig J, Heinemann SH, Wunder F, et al. Inactivation properties of voltage-gated K+ channels altered by presence of beta-subunit. Nature 1994;369:289–94.
- Starkus JG, Schlief T, Rayner MD, Heinemann SH. Unilateral exposure of Shaker B potassium channels to hyperosmolar solutions. Biophys J 1995;69:860–72.
- England SK, Uebele VN, Kodali J, et al. A Novel K+ Channel beta-subunit (hKv beta 1.3) is produced via alternative mRNA splicing. J Biol Chem 1995;270:28531–4.
- England SK, Uebele VN, Shear H, et al. Characterization of a voltage-gated K+ channel beta subunit expressed in human heart. Proc Natl Acad Sci USA 1995;92:6309–13.
- Tamargo J, Caballero R, Gómez R, Delpón E. I(Kur)/Kv1.5 channel blockers for the treatment of atrial fibrillation. Expert Opin Investig Drugs 2009;18:399–416.
- Fedida D. Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent. Expert Opin Investig Drugs 2007;16:519–32.
- Wettwer E, Hála O, Christ T, et al. Role of IKur in controlling action potential shape and contractility in the human atrium – influence of chronic atrial fibrillation. Circulation 2004;110:2299–306.
- Fedida D, Orth PMR, Chen JYC, et al. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol 2005;16:1227–38.
- Fedida D, Eldstrom J, Hesketh JC, et al. Kv1.5 is an important component of repolarizing K + current in canine atrial myocytes. Circ Res 2003;93:744–51.
- Brendel J, Peukert S. Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias. Expert Opin Ther Pat 2002;12:1589–98,
- Guo X, Chen CL, Yang Q, et al. Effects of a novel class III antiarrhythmic agent, CPUY11018, on rat atrial fibrillation. Drug Develop Res 2010;71:303–12.
- Chodoeva A, Bosc JJ, Guillon J, et al. 8-O-Azeloyl-14-benzoylaconine: a new alkaloid from the roots of Aconitum karacolicum Rapcs and its antiproliferative activities. Bioorg Med Chem 2005;13:6493–501.
- Tai YT, But PPH, Young K, Lau CP. Cardiotoxicity after accidental herb-induced aconite poisoning. Lancet 1992;340:1254–6.
- Fu M, Li RX, Fan L, et al. Sarcoplasmic reticulum Ca2+ release channel ryanodine receptor (RyR2) plays a crucial role in aconitine-induced arrhythmias. Biochem Pharmacol 2008;75:2147–56.
- Bartosova L, Novak F, Bebarova M, et al. Antiarrhythmic effect of newly synthesized compound 44Bu on model of aconitine-induced arrhythmia – compared to lidocaine. Eur J Pharmacol 2007;575:127–33.